Vantage Biosciences Overview
- Year Founded
-
2023
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Early Stage VC
- Investors
-
1
Vantage Biosciences General Information
Description
Developer of an oral therapeutic platform intended to rate the root cause of vision loss resulting from diabetes. The company's platform offers a novel, oral treatment for inflammatory conditions by targeting the root drivers of inflammation, enabling patients to reduce the burden of diabetic eye diseases and preserve vision at risk.
Contact Information
Website
www.vantage-biosciences.comCorporate Office
- 78 Pall Mall
- London SW1Y 5ES
- England, United Kingdom
Corporate Office
- 78 Pall Mall
- London SW1Y 5ES
- England, United Kingdom
Vantage Biosciences Timeline
Vantage Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 01-Jul-2024 | Completed | Clinical Trials - Phase 2 | |||
| 1. Early Stage VC | 19-Jul-2023 | Completed | Clinical Trials - Phase 2 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Vantage Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Vantage Biosciences Patents
Vantage Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2830157-A1 | Guanidine compound | Active | 15-Mar-2011 | ||
| CA-2830157-C | Guanidine compound | Active | 15-Mar-2011 | ||
| US-20130143860-A1 | Guanidine compound | Active | 15-Mar-2011 | ||
| US-20140100210-A1 | Guanidine compound | Active | 15-Mar-2011 | ||
| US-20150203480-A1 | Guanidine compound | Active | 15-Mar-2011 | C07D413/12 |
Vantage Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Vantage Biosciences Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ALSA Ventures | Venture Capital | Minority |
Vantage Biosciences FAQs
-
When was Vantage Biosciences founded?
Vantage Biosciences was founded in 2023.
-
Where is Vantage Biosciences headquartered?
Vantage Biosciences is headquartered in London, United Kingdom.
-
What is the size of Vantage Biosciences?
Vantage Biosciences has 3 total employees.
-
What industry is Vantage Biosciences in?
Vantage Biosciences’s primary industry is Drug Discovery.
-
Is Vantage Biosciences a private or public company?
Vantage Biosciences is a Private company.
-
What is Vantage Biosciences’s current revenue?
The current revenue for Vantage Biosciences is .
-
How much funding has Vantage Biosciences raised over time?
Vantage Biosciences has raised $2.5M.
-
Who are Vantage Biosciences’s investors?
ALSA Ventures has invested in Vantage Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
